Alector prices $75 million underwritten offering at $2.05 per share
- Alector Inc. priced an underwritten offering of 36,600,000 shares at $2.05 per share
- Gross proceeds expected to reach $75,030,000.00 before deducting expenses
- Offering price represents a 7.3% premium over the October 15, 2026 closing price
- Net proceeds will fund research, development, manufacturing, and general corporate purposes
*this image is generated using AI for illustrative purposes only.
Alector Inc. announced the pricing of an underwritten offering of common stock, selling 36,600,000 shares at $2.05 per share. The pricing represents a premium of approximately 7.3% over the closing price on October 15, 2026.
The gross proceeds from this offering are expected to be $75,030,000.00 before deducting underwriting discounts, commissions, and other estimated offering expenses. All shares offered are being sold directly by Alector. The transaction is expected to close on or about October 19, 2026, subject to customary closing conditions.
Offering Details and Investors
The financing includes participation from both new and existing investors. Key participants include TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital, among others. Morgan Stanley & Co. LLC and BTIG, LLC are acting as joint lead book-running managers for the offering.
| Metric | Value |
|---|---|
| Shares Sold | 36,600,000 |
| Price Per Share | $2.05 |
| Gross Proceeds | $75,030,000.00 |
| Premium to Close | ~7.3% |
| Expected Close Date | October 19, 2026 |
Use of Proceeds
Alector anticipates using the net proceeds for general corporate purposes. These purposes may include:
- Research, development, and manufacturing of product candidates
- Working capital and capital expenditures
- Other corporate expenses
- Acquisitions of or strategic transactions in complementary products, technologies, or businesses
What the Numbers Show
The offering price of $2.05 per share marks a distinct divergence from typical discounted secondary offerings often seen in the biotechnology sector. By pricing at a 7.3% premium to the previous day's closing price, the deal signals strong institutional demand despite the dilution of 36.6 million shares. The gross raise of $75 million provides a specific capital injection, though the final net amount will be reduced by underwriting fees and expenses not detailed in the announcement.
Regulatory and Legal Context
The securities are being offered pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement related to the offering will be filed with the SEC and made available on its website. Copies of the prospectus supplement and accompanying prospectus can be obtained from Morgan Stanley & Co. LLC or BTIG, LLC when available.
This press release does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such activity would be unlawful prior to registration or qualification.
How will the $75 million capital injection specifically accelerate the clinical trial timelines for Alector's lead neurodegenerative disease candidates?
What strategic acquisitions or partnerships might Alector pursue given the explicit mention of using proceeds for complementary businesses?
How does the 7.3% pricing premium influence investor sentiment and potential share price volatility following the October 19 closing date?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
